Company intelligence / Profile preview
Qilu Pharmaceutical
Jinan, Shandong, 中国（China）en.qilu-pharma.com ↗
- Ownership
- Private
- Employees
- ~39000
- Development stage
- Other
01
Overview
Qilu Pharmaceutical has launched over 300 products with more than 55 “First-to-launch” in China. The company maintains a robust pipeline of over 200 generics, 80+ innovative drugs/projects—including at least 10 in clinical stages—and more than 20 biosimilars. It exports finished dosage forms and APIs worldwide with approvals from major regulatory agencies such as US FDA and EMA.
- Therapeutic areas
- PulmonologyCardiovascularOphthalmologyWomen's HealthOncologyNeurologyInfectious Diseases
- Modalities
- Small moleculesbiosimilarsmonoclonal antibodies (mAbs)chemical drugsbiological products
- Industry
- Pharma
02
Drug pipeline
106 assets105 more assets in the full pipeline.
Beyond the preview
Go deeper on Qilu Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Qilu Pharmaceutical.